Comparative Pharmacology
Head-to-head clinical analysis: PARASAL versus TRECATOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARASAL versus TRECATOR.
PARASAL vs TRECATOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Uncertain; may involve inhibition of prostaglandin synthesis in the CNS, weak inhibition of COX-1 and COX-2, and activation of TRPA1 channels.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the formation of the initiation complex and causing misreading of mRNA.
4 g (8 capsules or 2 sachets) orally every 6 hours; maximum 16 g per day.
15-20 mg/kg/day orally once daily; maximum 1 g/day.
None Documented
None Documented
Terminal half-life: 10-15 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment.
Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged in hepatic impairment; clinically relevant for once-daily or thrice-weekly dosing
Renal: 50-60% as unchanged drug; biliary/fecal: 20-30% as metabolites; total recovery: >80% within 24 hours.
Renal: 70-80% as unchanged drug; fecal: <20%; biliary: minor
Category C
Category C
Antituberculosis Agent
Antituberculosis Agent